- Vaccino contro l’hantavirus nel 2026?2¢2%
No hantavirus vaccine is positioned for approval or broad availability by the end of 2026. All active candidates remain in preclinical or very early clinical stages, with no advanced human efficacy trials underway. Recent mRNA platforms, including single-dose candidates tested in hamsters at UTMB and work by Moderna with Korea University, have shown strong protection in rodent models against strains like Andes virus, yet these have not entered Phase 1 human testing. Older DNA vaccine efforts have completed limited Phase 1 safety studies but lack large-scale efficacy data or regulatory advancement. The 2026 cruise-ship outbreak has heightened awareness and prompted some funding discussions, yet development timelines for new vaccines—especially against regionally variable hantaviruses—typically span multiple years absent an extraordinary acceleration program. Realistic shifts before year-end would require unprecedented regulatory fast-tracking or emergency authorization based on preliminary data, scenarios viewed as improbable given current pipelines and resource constraints.
Regole
Questo mercato si risolverà a favore di "Sì" se un qualsiasi vaccino destinato agli esseri umani e che immunizza contro gli hantavirus (inclusa la sindrome polmonare da hantavirus (HPS) o la febbre emorragica con sindrome renale (HFRS)) riceve la piena approvazione della Food and Drug Administration statunitense tra la creazione del mercato e 31 dicembre 2026, 23:59 ET. Altrimenti, questo mercato si risolverà su "No". La fonte primaria per la risoluzione di questo mercato saranno le informazioni ufficiali della FDA, compreso il suo elenco dei vaccini approvati (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states); tuttavia, potrà essere utilizzato anche il consenso delle notizie provenienti da fonti attendibili.
Traduzione automatica. In caso di controversia, fa fede l'originale.